Chevallier, Patrice <br/><br/>
Trastuzumab for treatment of refractory/relapsed HER2-positive adult B-ALL: results of a phase 2 GRAALL study.  [electronic resource] 

 -  Blood  Mar 2012 
 - 2474-7 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1528-0020 
<br/><br/><label>Standard No.: </label>10.1182/blood-2011-11-390781  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antibodies, Monoclonal, Humanized--therapeutic use<br/>Antineoplastic Agents--therapeutic use<br/>Drug Resistance, Neoplasm--drug effects<br/>Female<br/>Flow Cytometry<br/>Humans<br/>Male<br/>Middle Aged<br/>Neoplasm Recurrence, Local--drug therapy<br/>Precursor B-Cell Lymphoblastic Leukemia-Lymphoma--drug therapy<br/>Receptor, ErbB-2--metabolism<br/>Trastuzumab<br/>Treatment Outcome<br/>Young Adult